Compounded tirzepatide is one of the most common questions prescribers now field from patients, and the answers have changed sharply. What was widely available and inexpensive during the shortage is now legally constrained, and the safety and liability picture has come into much clearer focus.
This prescriber guide covers where compounded tirzepatide stands with the FDA as of September 2026, the quality and sourcing concerns that make it risky, the liability and documentation issues for clinicians, how to counsel patients who ask for it, and how to transition patients to FDA-approved products. It is the companion to our 2026 regulatory update on compounded semaglutide, and both expand on our complete prescriber’s guide to GLP-1 medications for weight management.
The legal basis for compounding tirzepatide has effectively closed. Compounding copies of an approved drug is permitted only while that drug is officially in shortage, and the FDA removed tirzepatide from its shortage list in December 2024 (Drug Topics, 2025). Once the compounding grace periods expired, routine large-scale compounding of tirzepatide copies was no longer lawful.
The FDA has since moved to make this permanent. On April 30, 2026, it proposed a rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would bar outsourcing facilities from bulk-compounding these agents regardless of future market conditions (U.S. Food and Drug Administration, 2026a). The agency stated it did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. The comment period has closed, and as of September 2026 the rule remains proposed rather than final (Federal Register, 2026).
Narrow 503A exceptions remain for genuine, documented patient-specific needs, but the overall direction is unmistakable: the agency is closing large-scale GLP-1 compounding for good (Pharmacy Times, 2026). Because this is a live decision, re-verify the current status before relying on it.
A proposed rule is not a final rule. Until the FDA publishes a final determination, the 503B position can still shift — and a page, protocol or patient handout that states it as settled will be wrong the day it changes. Check the docket (FDA-2018-N-3240) before you cite the status in writing.
Beyond legality, compounded tirzepatide carries real safety concerns that every prescriber should be able to articulate. The FDA has documented a substantial safety signal: as of May 31, 2026, it had received more than 730 adverse event reports associated with compounded tirzepatide, alongside 990 associated with compounded semaglutide (U.S. Food and Drug Administration, 2026b). Because state-licensed pharmacies are not required to report, the true numbers are almost certainly higher, and the reports themselves do not establish causation.
Several problems drive those reports. Dosing errors are prominent: patients measuring and self-administering from multi-dose vials have received incorrect — sometimes many-fold excessive — doses, with some requiring hospitalization. Sourcing is another: the FDA has established a green list import alert (66-80) targeting GLP-1 active pharmaceutical ingredients of quality concern, because some compounded product has relied on foreign-sourced or unverified raw material, including salt forms that are different active ingredients without established safety data. Storage adds a third: these injectables require refrigeration, and product that arrives warm or insufficiently cooled may be degraded before the first dose.
The same federal logic reaches further than the approved molecules. The FDA is explicit that retatrutide and cagrilintide cannot be used in compounding at all, because neither has been approved for any condition — a point worth knowing before a patient arrives asking about a product they found online. Our guide to retatrutide’s investigational dosing data covers what the trial evidence does and does not support.
Unlike an FDA-approved product manufactured to a consistent standard, compounded tirzepatide varies with the pharmacy, the ingredient source, and the supply chain. The practical differences are worth having in front of you when a patient pushes back:
| Factor | Compounded tirzepatide | FDA-approved Zepbound® |
|---|---|---|
| Legal basis | Shortage pathway closed Dec 2024; 503B exclusion proposed Apr 2026; narrow 503A exceptions only | FDA-approved for chronic weight management |
| Manufacturing standard | Varies by pharmacy; no premarket review of the finished product | Consistent, inspected manufacturing to an approved specification |
| Dosing format | Often vials dosed in “units” or volumes; patient draws the dose | Single-dose pens or vials at defined milligram strengths |
| Ingredient sourcing | May be foreign-sourced or unverified; salt forms are different active ingredients (import alert 66-80) | Qualified supply chain under the approved application |
| Cold chain | Shipped direct-to-patient; may arrive warm or insufficiently cooled | Validated distribution with defined storage conditions |
| Documented adverse events | 730+ FDA reports as of May 31, 2026, largely dosing errors | Captured in labeling and post-market surveillance |
| Self-pay cost | Historically low, which is why patients ask | $299–$449/month for single-dose vials via the manufacturer’s self-pay program |
For the prescriber, these concerns translate directly into liability. Prescribing or facilitating access to non-compliant compounded tirzepatide can expose a clinician to regulatory action, state board scrutiny, and malpractice risk — and the documented adverse events make foreseeability harder to argue away if something goes wrong.
Two rules keep a practice on safe ground. First, cost savings alone do not justify compounding when the approved product is commercially available; “it’s cheaper” is not a lawful or defensible clinical rationale. Second, if a genuinely patient-specific need exists, document it explicitly — the specific clinical reason, the product and pharmacy used, and the informed-consent conversation about risks.
The safest posture is to default to the approved products and treat any compounded use as a rare, well-documented exception rather than a routine cost play. Structured programs such as IAPAM’s CME-accredited GLP-1 prescribing training build these compliance and documentation habits into a repeatable protocol.
If a compounded-product decision is ever questioned, the record that helps you is the one written at the time: the documented patient-specific reason, the named 503A pharmacy, the consent discussion, and the date. A note added later reads as reconstruction, not protocol.
Many patients will ask about compounded tirzepatide directly, often because they used it during the shortage or saw it advertised online at a low price. The conversation goes better when you lead with empathy rather than a flat refusal.
Acknowledge the real driver — usually cost — and then explain plainly why the landscape has changed: the shortage is over, large-scale compounding is no longer permitted, and the FDA has logged hundreds of adverse events tied to compounded versions, including serious dosing errors. Emphasize that the approved products are manufactured to a consistent standard that compounded versions cannot guarantee.
Crucially, pair the “no” with a “here’s what we can do.” The approved products are far more affordable through manufacturer self-pay programs than they were during the shortage: Zepbound® single-dose vials were repriced in December 2025 to $299 per month at the 2.5 mg starting dose and $399–$449 at higher doses through the manufacturer’s direct self-pay channel (Eli Lilly and Company, 2025). That narrows the cost gap that made compounding attractive in the first place. Where a patient does have coverage, our prior authorization playbook covers how to get the approved product paid for rather than worked around. Patients are far more receptive when the safer option is also a workable one.
Many practices are now moving patients from compounded tirzepatide to approved Zepbound®. Do this deliberately rather than assuming a one-to-one swap. Compounded products vary in concentration and are often dosed in “units” or volumes that do not map cleanly onto the approved milligram strengths, so treat the transition as a fresh, structured titration rather than a like-for-like continuation.
In practice, that means selecting an appropriate approved starting or step dose based on the patient’s tolerance and history and titrating on the standard four-week schedule, watching tolerability closely. For the full protocol, see our tirzepatide titration and dosing guide.
Reassess candidacy and contraindications at the transition point — a patient who started on a compounded product may never have been screened against the approved label in the first place, so run the full contraindication and patient-selection review as if this were a new start. Document the switch and its rationale, and set expectations that the approved product’s dosing may feel different from what the patient used before.
Semaglutide and tirzepatide changed what patients expect from their providers. IAPAM’s GLP-1 certification gives you the protocols, titration schedules, monitoring parameters and side-effect management to run a medically supervised weight management program with confidence.
What the certification covers
For MD/DO, NP, APRN, PA, RN and other licensed providers
GLP-1 Essentials for Weight Loss — self-paced
3 CMEs · 3-5 hours · 24/7 access
Certified Medical Weight Management Provider™ (CWMP)
6 CMEs · 8-10 hours · 24/7 access
Questions? Call 1-866-211-6901
Largely no for routine use. The tirzepatide shortage was resolved in December 2024, ending the legal basis for large-scale compounding of copies, and on April 30, 2026 the FDA proposed permanently excluding tirzepatide from the 503B bulks list. That comment period has closed and, as of September 2026, the rule is proposed but not final. Narrow 503A exceptions remain for documented, patient-specific needs. Re-verify the current FDA status before relying on it.
The FDA has received more than 730 adverse event reports associated with compounded tirzepatide as of May 31, 2026, alongside 990 for compounded semaglutide — more than 1,700 reports across the two. The reports are driven largely by dosing errors, some requiring hospitalization, plus concerns about unverified foreign-sourced ingredients, salt forms with no established safety data, and inadequate cold-chain storage. Because state-licensed pharmacies are not required to report, the true totals are almost certainly higher.
Only in narrow circumstances — a documented, patient-specific clinical need, through a 503A pharmacy under a valid prescription. Cost savings alone are not a lawful justification when the approved product is commercially available, and the clinical rationale, the pharmacy used, and the informed-consent conversation should all be documented.
Lead with empathy for the cost concern, explain that the shortage is over and the FDA has logged serious safety issues with compounded versions, and offer the approved product as a now-more-affordable alternative. Zepbound® single-dose vials are priced at $299 to $449 per month through Lilly’s self-pay program, which narrows the cost gap that made compounding attractive during the shortage.
Treat it as a fresh, structured titration rather than a one-to-one swap, because compounded concentrations and unit-based dosing do not map cleanly onto approved milligram doses. Select an appropriate approved dose based on tolerance and history, titrate on the standard four-week schedule, and re-check candidacy and contraindications at the transition point.
No. Salt forms are different active ingredients without established safety and efficacy data, which is a specific reason the FDA has cautioned against unapproved compounded GLP-1 products. The agency has also established a green list import alert, 66-80, covering GLP-1 active pharmaceutical ingredients of quality concern.
No. The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, and neither has been approved for any condition. Products marketed to patients or clinics as compounded retatrutide fall outside any lawful compounding pathway, regardless of how they are labeled.
As of September 2026, compounded tirzepatide has shifted from a shortage-era default to a narrow, high-risk exception. The shortage is resolved, large-scale compounding is no longer permissible, the FDA has documented a real safety signal, and a proposed rule would close the door permanently. The prescriber’s job is to default to the approved products, reserve compounding for genuine documented needs, counsel patients honestly, and transition them safely — while re-verifying the FDA’s position as it evolves.
To prescribe within the current rules with confidence, IAPAM’s GLP-1 certification training — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — keeps your protocols current and defensible. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training certification for nurse practitioners and other licensed providers.
Explore GLP-1 Certification Training →
Disclaimer: This article is for informational and educational purposes only and does not constitute legal or medical advice. Compounding regulations are actively changing; the status described here is current as of September 2026. Always verify the current FDA position and your state board’s rules before making any prescribing or sourcing decision.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.